{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:41:56Z","timestamp":1788266516237,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873431"],"award-info":[{"award-number":["81873431"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31400692"],"award-info":[{"award-number":["31400692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81520108005"],"award-info":[{"award-number":["81520108005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20181164"],"award-info":[{"award-number":["BK20181164"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5808-9","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T14:03:13Z","timestamp":1560780193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Mengqiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingpeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgeng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-9370","authenticated-orcid":false,"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"issue":"Suppl 1","key":"5808_CR1","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S0049-3848(12)70013-0","volume":"129","author":"KL Lowe","year":"2012","unstructured":"Lowe KL, Navarro-Nunez L, Waston SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012;129(Suppl 1):S30\u20137.","journal-title":"Thromb Res"},{"key":"5808_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pharmthera.2015.11.005","volume":"157","author":"B Tesfamariam","year":"2016","unstructured":"Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112\u20139.","journal-title":"Pharmacol Ther"},{"key":"5808_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1172\/JCI200423823","volume":"114","author":"GP Gupta","year":"2004","unstructured":"Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest. 2004;114:1691\u20133.","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"5808_CR4","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/S0049-3848(14)50025-4","volume":"133","author":"D Stegner","year":"2014","unstructured":"Stegner D, Dutting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133(Suppl 2):S149\u201357.","journal-title":"Thromb Res"},{"key":"5808_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9440(10)62311-5","volume":"166","author":"V Schacht","year":"2005","unstructured":"Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913\u201321.","journal-title":"Am J Pathol"},{"key":"5808_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2006.03.010","volume":"9","author":"A Wicki","year":"2006","unstructured":"Wicki A, Lehembre F, Wick N, et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261\u201372.","journal-title":"Cancer Cell"},{"key":"5808_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cncr.22061","volume":"107","author":"P Yuan","year":"2006","unstructured":"Yuan P, Temam S, El-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107:563\u20139.","journal-title":"Cancer."},{"key":"5808_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1440-1827.2005.01791.x","volume":"55","author":"N Kimura","year":"2005","unstructured":"Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int. 2005;55:83\u20136.","journal-title":"Pathol Int"},{"key":"5808_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.humpath.2005.01.019","volume":"36","author":"NG Ordonez","year":"2005","unstructured":"Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372\u201380.","journal-title":"Hum Pathol"},{"key":"5808_CR10","first-page":"243","volume":"79","author":"W Weninger","year":"1999","unstructured":"Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999;79:243\u201351.","journal-title":"Lab Invest"},{"key":"5808_CR11","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1038\/sj.onc.1207869","volume":"23","author":"Y Kato","year":"2004","unstructured":"Kato Y, Sasagawa I, Kaneko M, et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004;23:8552\u20136.","journal-title":"Oncogene."},{"issue":"4","key":"5808_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00428-005-0133-x","volume":"448","author":"J Shibahara","year":"2006","unstructured":"Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448(4):493\u20139.","journal-title":"Virchows Arch"},{"key":"5808_CR13","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1158\/0008-5472.CAN-10-3228","volume":"71","author":"A Hoshino","year":"2011","unstructured":"Hoshino A, Ishii G, Ito T, et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res. 2011;71:4769\u201379.","journal-title":"Cancer Res"},{"key":"5808_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2007.13.4072","volume":"26","author":"H Kawaguchi","year":"2008","unstructured":"Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008;26:354\u201360.","journal-title":"J Clin Oncol"},{"key":"5808_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ijc.23611","volume":"123","author":"A Kawase","year":"2008","unstructured":"Kawase A, Ishii G, Nagai K, et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer. 2008;123:1053\u20139.","journal-title":"Int J Cancer"},{"key":"5808_CR16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2353\/ajpath.2007.060790","volume":"170","author":"A Kunita","year":"2007","unstructured":"Kunita A, Kashima TG, Morishita Y, et al. The platelet aggregation-inducing factor aggrus\/podoplanin promotes pulmonary metastasis. Am J Pathol. 2007;170:1337\u201347.","journal-title":"Am J Pathol"},{"key":"5808_CR17","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1242\/jcs.03218","volume":"119","author":"E Martin-Villar","year":"2006","unstructured":"Martin-Villar E, Megias D, Castel S, et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 2006;119:4541\u201353.","journal-title":"J Cell Sci"},{"key":"5808_CR18","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/labinvest.3780185","volume":"80","author":"FG Scholl","year":"2000","unstructured":"Scholl FG, Gamallo C, Quintanilla M. Ectopic expression of PA2.26 antigen in epidermal keratinocytes leads to destabilization of adherens junctions and malignant progression. Lab Invest. 2000;80:1749\u201359.","journal-title":"Lab Invest"},{"key":"5808_CR19","doi-asserted-by":"publisher","first-page":"51599","DOI":"10.1074\/jbc.M309935200","volume":"278","author":"Y Kato","year":"2003","unstructured":"Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus\/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003;278:51599\u2013605.","journal-title":"J Biol Chem"},{"key":"5808_CR20","doi-asserted-by":"publisher","first-page":"25993","DOI":"10.1074\/jbc.M702327200","volume":"282","author":"K Suzuki-Inoue","year":"2007","unstructured":"Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993\u20136001.","journal-title":"J Biol Chem"},{"key":"5808_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/jb\/mvr079","volume":"150","author":"K Suzuki-Inoue","year":"2011","unstructured":"Suzuki-Inoue K. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem. 2011;150:127\u201332.","journal-title":"J Biochem"},{"key":"5808_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2005-05-1994","volume":"107","author":"K Suzuki-Inoue","year":"2006","unstructured":"Suzuki-Inoue K, Fuller GL, Garcia A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107:542\u20139.","journal-title":"Blood."},{"key":"5808_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.bbrc.2006.08.171","volume":"349","author":"Y Kato","year":"2006","unstructured":"Kato Y, Kaneko MK, Kuno A, et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun. 2006;349:1301\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5808_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cas.13475","volume":"109","author":"X Zhao","year":"2018","unstructured":"Zhao X, Pan Y, Ren W, et al. Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis. Cancer Sci. 2018;109(2):403\u201311.","journal-title":"Cancer Sci"},{"key":"5808_CR25","first-page":"25","volume":"32","author":"L Qu","year":"2016","unstructured":"Qu L, Zhao X, Fu J, et al. Stable expression of recombinant human podoplanin in Chinese hamster ovary (CHO) cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32:25\u20138.","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"5808_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2004-02-0434","volume":"104","author":"E Camerer","year":"2004","unstructured":"Camerer E, Qazi AA, Duong DN, et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104:397\u2013401.","journal-title":"Blood."},{"key":"5808_CR27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1152\/physrev.1983.63.3.1114","volume":"63","author":"AB Malik","year":"1983","unstructured":"Malik AB. Pulmonary microembolism. Physiol Rev. 1983;63:1114\u2013207.","journal-title":"Physiol Rev"},{"issue":"6","key":"5808_CR28","first-page":"1713","volume":"143","author":"C Philippe","year":"1993","unstructured":"Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol. 1993;143(6):1713\u201323.","journal-title":"Am J Pathol"},{"key":"5808_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123\u201334.","journal-title":"Nat Rev Cancer"},{"key":"5808_CR30","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","volume":"23","author":"CP Klerk","year":"2005","unstructured":"Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130\u20135.","journal-title":"J Clin Oncol"},{"key":"5808_CR31","doi-asserted-by":"publisher","first-page":"24494","DOI":"10.1074\/jbc.M110.130575","volume":"285","author":"K Suzuki-Inoue","year":"2010","unstructured":"Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic\/neonatal lethality of CLEC-2-deficient mice by blood\/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010;285:24494\u2013507.","journal-title":"J Biol Chem"},{"key":"5808_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1042\/bj2910677","volume":"291","author":"T Eichholtz","year":"1993","unstructured":"Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291 ( Pt 3:677\u201380.","journal-title":"Biochem J"},{"issue":"11","key":"5808_CR33","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/j.1538-7836.2009.03586.x","volume":"7","author":"SS Smyth","year":"2009","unstructured":"Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7(11):1759\u201366.","journal-title":"J Thromb Haemost"},{"key":"5808_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073609","volume":"8","author":"S Takagi","year":"2013","unstructured":"Takagi S, Sato S, Oh-hara T, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus\/podoplanin and CLEC-2. PLoS One. 2013;8:e73609.","journal-title":"PLoS One"},{"issue":"8","key":"5808_CR35","first-page":"9390","volume":"8","author":"S Tajima","year":"2015","unstructured":"Tajima S, Fukayama M. Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors. Int J Clin Exp Pathol. 2015;8(8):9390\u20136.","journal-title":"Int J Clin Exp Pathol"},{"key":"5808_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-018-0322-1","volume":"6","author":"MZ Afzal","year":"2018","unstructured":"Afzal MZ, Mabaera R, Shirai K. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. J Immunother Cancer. 2018;6:13.","journal-title":"J Immunother Cancer"},{"key":"5808_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-017-1307-4","volume":"15","author":"R Huang","year":"2017","unstructured":"Huang R, Andersen LMK, Rofstad EK. Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts. J Transl Med. 2017;15:203.","journal-title":"J Transl Med"},{"issue":"2","key":"5808_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, et al. Circulating tumor DNA predicts survival in patients with resected high risk stage II\/III melanoma. Ann Oncol. 2018;29(2):490\u20136.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5808-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T23:13:26Z","timestamp":1592262806000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5808-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5808"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5808-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"6 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human venous blood was collected from healthy donors in compliance with the Declaration of Helsinki, which was also approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"599"}}